Clinical Study on the effects of add-on therapy with Montelukast in treatment of Henoch-Schnlein purpura

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002597

Enrollment

Unknown

Registered

2012-10-18

Start date

2006-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Henoch-Sch?nlein purpura(HSP)

Interventions

Routine-treated group:Routine treatment

Routine+Montelukast-treated group:Routine treatment+Montelukast

Eligibility

Sex/Gender

All

Age

4 Years to 9 Years

Inclusion criteria

Inclusion criteria: The patients are diagnosed according to EULAR/PRINTO/PRES criteria for HSP: Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schnlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69(5):798-806.

Exclusion criteria

Exclusion criteria: HSP Patients with previous treatment

Design outcomes

Primary

Measure	Time frame
Severity Scale Score for severity ratings of HSP;	—

Countries

China

Contacts

Public ContactSheng-Hua Wu

kad-yc@163.com+86 13813848630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026